Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.77 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030292 | 0.87 | ESR1 (1.00) | ESR1RORCTP53ALDH1A1NPSR1 | |
| SCHEMBL4035727 | 0.86 | ESR1 (0.57) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4031909 | 0.86 | ESR1 (0.76) | ESR1RORCALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL4026981 | 0.83 | ESR1 (0.93) | ESR1RORCTP53MEN1CYP1A2 | |
| SCHEMBL4025562 | 0.83 | ESR1 (0.71) | ESR1RORCPDE4BALDH1A1NPSR1 | |
| SCHEMBL4031338 | 0.82 | ESR1 (0.75) | ESR1RORCPDE4APDE4BPDE4C | |
| SCHEMBL4025914 | 0.81 | ESR1 (0.51) | ESR1RORCMAPT | |
| SCHEMBL4031726 | 0.79 | ESR1 (1.00) | ESR1RORCTP53ALDH1A1NPSR1 | |
| SCHEMBL5397380 | 0.79 | ESR1 (0.56) | ESR1RORCMEN1MAPTKMT2A | |
| SCHEMBL4032548 | 0.78 | ESR1 (0.55) | ESR1TP53PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885RORC 142/4885TP53 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.